{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:20Z","timestamp":1793831300803,"version":"4.6.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.autrev.2023.103506","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T02:20:56Z","timestamp":1703125256000},"page":"103506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data"],"prefix":"10.1016","volume":"23","author":[{"given":"Benjamin","family":"Thoreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103506_bb0005","first-page":"2200879","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"2022","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0010","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0030","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival","volume":"63","author":"Humbert","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0035","first-page":"53","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103506_bb0045","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0050","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/jamacardio.2017.3882","article-title":"Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension","volume":"2","author":"Assad","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0055","first-page":"51","article-title":"Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis","author":"Coghlan","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0060","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.37838","article-title":"Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension","volume":"65","author":"Valerio","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.00008611","article-title":"Pulmonary vascular resistances during exercise in normal subjects: a systematic review","volume":"39","author":"Kovacs","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0070","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0075","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1183\/13993003.00990-2016","article-title":"Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis","volume":"48","author":"Stamm","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152033","article-title":"Left ventricular diastolic dysfunction in systemic sclerosis: clinical, immunological and survival differences in the Spanish RESCLE registry","volume":"55","author":"Gonz\u00e1lez Garc\u00eda","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0085","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s10067-021-05804-6","article-title":"Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China","volume":"40","author":"Hui","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0780","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103506_bb0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","article-title":"Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension","volume":"79","author":"Xanthouli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0095","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2021","article-title":"Pulmonary hypertension phenotypes in patients with systemic sclerosis","volume":"30","author":"Haque","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2023.103506_bb0100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/0961203312456751","article-title":"Distinct phenotypes in mixed connective tissue disease: subgroups and survival","volume":"21","author":"Szodoray","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2023.103506_bb0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/16000617.0011-2016","article-title":"Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Flament","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2023.103506_bb0110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00101211","article-title":"Survival in pulmonary hypertension in Spain: insights from the Spanish registry","volume":"40","author":"Escribano-Subias","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0150","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1183\/09031936.00182813","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients","volume":"44","author":"Hao","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1378\/chest.10-2327","article-title":"Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era","volume":"140","author":"Zhang","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0235","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/rheumatology\/kes140","article-title":"Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort","volume":"51","author":"Shirai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103506_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0130","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0135","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.23303","article-title":"Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases","volume":"58","author":"Jais","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0160","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0165","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0170","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","author":"Hao","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2023.103506_bb0175","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1191\/096120300678828361","article-title":"Primary and secondary pulmonary hypertension in systemic lupus erythematosus","volume":"9","author":"Pan","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2023.103506_bb0180","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/rheumatology\/kep203","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus","volume":"48","author":"Prabu","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103506_bb0185","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s10067-013-2307-2","article-title":"Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature","volume":"32","author":"Yang","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0190","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.semarthrit.2020.06.005","article-title":"Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: a national cohort study in Taiwan","volume":"50","author":"Lin","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0195","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/1756-185X.13478","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: baseline characteristics and risk factors","volume":"22","author":"Zhang","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2017.08.014","article-title":"Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry","volume":"153","author":"Hachulla","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/annrheumdis-2018-214197","article-title":"Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus","volume":"78","author":"Sun","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0210","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/01.CIR.68.6.1182","article-title":"Cardiovascular manifestations of mixed connective tissue disease in adults","volume":"68","author":"Alpert","year":"1983","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L","article-title":"Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings","volume":"42","author":"Burdt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0220","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00005792-198403000-00003","article-title":"A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease","volume":"63","author":"Sullivan","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103506_bb0225","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/art.21131","article-title":"The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)","volume":"52","author":"Wigley","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0230","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/kes430","article-title":"Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature","volume":"52","author":"Gunnarsson","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103506_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead055","article-title":"In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicenter study","author":"Chaigne","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103506_bb0245","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3899\/jrheum.121272","article-title":"Clinical course, prognosis, and causes of death in mixed connective tissue disease","volume":"40","author":"Hajas","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0250","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/srma43","article-title":"The prevalence of pulmonary arterial hypertension in patients with mixed connective tissue disease: a systematic review and meta-analysis","author":"Hassan","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0255","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijcard.2017.01.097","article-title":"Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China","volume":"236","author":"Zhao","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","article-title":"Pulmonary arterial hypertension: a rare complication of primary Sj\u00f6gren syndrome: report of 9 new cases and review of the literature","volume":"86","author":"Launay","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103506_bb0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000485631","article-title":"Association between rheumatoid arthritis and pulmonary hypertension: data from the French pulmonary hypertension registry","volume":"95","author":"Montani","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.autrev.2023.103506_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004911","article-title":"Pulmonary arterial hypertension in idiopathic inflammatory myopathies: data from the French pulmonary hypertension registry and review of the literature","volume":"95","author":"Sanges","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103506_bb0275","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/art.40862","article-title":"Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis","volume":"71","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0280","doi-asserted-by":"crossref","first-page":"1801899","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0285","first-page":"53","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2332\/allergolint.11-RAI-0337","article-title":"A histopathological study of pulmonary hypertension in connective tissue disease","volume":"60","author":"Sasaki","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.autrev.2023.103506_bb0295","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0300","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"G\u00fcnther","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0305","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfm\u00fcller","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2023.103506_bb0310","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.lpm.2010.10.017","article-title":"Pulmonary veno-occlusive disease: the b\u00eate noire of pulmonary hypertension in connective tissue diseases?","volume":"40","author":"O\u2019Callaghan","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0315","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/ard.34.5.457","article-title":"Lupus cor pulmonale with electron microscope and immunofluroescent antibody studies","volume":"34","author":"Yeo","year":"1975","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0320","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0049-0172(84)90015-5","article-title":"Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus","volume":"13","author":"Quismorio","year":"1984","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1161\/CIRCULATIONAHA.114.009309","article-title":"Update on chronic thromboembolic pulmonary hypertension","volume":"130","author":"Lang","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0330","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0335","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","article-title":"Chemokine RANTES in severe pulmonary arterial hypertension","volume":"165","author":"Dorfm\u00fcller","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0340","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1164\/rccm.200610-1559OC","article-title":"Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension","volume":"176","author":"Sanchez","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0345","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1183\/09031936.00104706","article-title":"Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0350","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00151313","article-title":"Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension","volume":"43","author":"Cracowski","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0355","article-title":"Pathophysiology of systemic sclerosis","volume":"50","author":"Thoreau","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.00094706","article-title":"Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.201105-0927OC","article-title":"Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension","volume":"185","author":"Perros","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0370","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","article-title":"Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension","volume":"186","author":"Savai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0375","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.drudis.2014.04.007","article-title":"Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first","volume":"19","author":"Cohen-Kaminsky","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2023.103506_bb0380","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/cvr\/cvz308","article-title":"Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator","volume":"116","author":"Huertas","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2023.103506_bb0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2019.00011","article-title":"Dendritic cell subsets and effector function in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"10","author":"van Uden","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103506_bb0390","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.chest.2016.01.004","article-title":"Regulatory T cell dysfunction in idiopathic, heritable and connective tissue-associated pulmonary arterial hypertension","volume":"149","author":"Huertas","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0395","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete Interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2023.103506_bb0400","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/annrheumdis-2011-200195","article-title":"IgG from patients with pulmonary arterial hypertension and\/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction","volume":"71","author":"Bussone","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0405","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1183\/09031936.00181410","article-title":"Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma","volume":"39","author":"Dib","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0410","first-page":"286","article-title":"High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension","volume":"23","author":"Karmochkine","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0415","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0420","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2023.103506_bb0425","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0430","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","article-title":"Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension","volume":"177","author":"Terrier","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0435","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.2008.104299","article-title":"Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease","volume":"69","author":"Terrier","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103506_bb0445","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/08916934.2013.812080","article-title":"Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension","volume":"46","author":"Arends","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2023.103506_bb0450","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0455","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0460","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.healun.2014.09.016","article-title":"Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) analysis","volume":"34","author":"Benza","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.autrev.2023.103506_bb0465","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0470","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0475","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103506_bb0480","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL registry","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0485","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1183\/09059180.00008211","article-title":"REVEAL: a contemporary US pulmonary arterial hypertension registry","volume":"21","author":"McGoon","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2023.103506_bb0490","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.41669","article-title":"Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0495","article-title":"Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis","author":"Distler","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103506_bb0500","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.chest.2018.05.002","article-title":"Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry (PHAROS)","volume":"154","author":"Kolstad","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0505","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1136\/annrheumdis-2012-202489","article-title":"Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era","volume":"72","author":"Launay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0510","doi-asserted-by":"crossref","first-page":"1800081","DOI":"10.1183\/13993003.00081-2018","article-title":"Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study","volume":"53","author":"Qian","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0515","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0520","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0525","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10067-013-2383-3","article-title":"Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years","volume":"33","author":"Fei","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0535","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0540","doi-asserted-by":"crossref","first-page":"1602275","DOI":"10.1183\/13993003.02275-2016","article-title":"Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort","volume":"49","author":"Vandecasteele","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0545","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0023-2019","article-title":"Screening for pulmonary arterial hypertension in systemic sclerosis","volume":"28","author":"Weatherald","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2023.103506_bb0550","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0555","first-page":"52","article-title":"Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension","author":"Weatherald","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0560","first-page":"53","article-title":"Diagnosis of pulmonary hypertension","author":"Frost","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0565","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.semarthrit.2015.07.002","article-title":"A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage","volume":"45","author":"Meune","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0570","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13075-017-1250-z","article-title":"Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme","volume":"19","author":"Morrisroe","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103506_bb0575","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103506_bb0580","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103506_bb0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0590","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0595","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.semarthrit.2018.10.010","article-title":"Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension","volume":"48","author":"Young","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103506_bb0600","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.jacc.2006.07.061","article-title":"Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers","volume":"48","author":"Hoeper","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0605","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0610","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0615","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0625","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0785","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0790","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0795","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0660","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","article-title":"Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - a subgroup analysis of the ARIES-E clinical trial","volume":"117","author":"Fischer","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0800","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0640","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0650","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0805","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0655","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2017.02.094","article-title":"Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease","volume":"235","author":"Gali\u00e8","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0810","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0815","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0820","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0825","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0830","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0835","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0840","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0620","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103506_bb0630","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0635","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0645","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0665","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.2282","article-title":"Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)","volume":"41","author":"McLaughlin","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2023.103506_bb0670","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0675","first-page":"1095","article-title":"Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"36","author":"Pan","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0680","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/1756-185X.14368","article-title":"Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: a systematic review","volume":"25","author":"Ding","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103506_bb0685","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2023.103506_bb0690","first-page":"282","article-title":"Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment","volume":"29","author":"Tanaka","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0695","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","article-title":"Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease","volume":"82","author":"Yasuoka","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2023.103506_bb0700","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1253\/circj.CJ-11-0473","article-title":"Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease","volume":"75","author":"Miyamichi-Yamamoto","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2023.103506_bb0705","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis associated pulmonary arterial hypertension: a multi-center, double-blind, randomized, placebo-controlled trial","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0710","doi-asserted-by":"crossref","first-page":"2002463","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension","volume":"59","author":"Toshner","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0715","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0961203311403347","article-title":"The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review","volume":"20","author":"Kato","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2023.103506_bb0720","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2023.103506_bb0725","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1165\/ajrcmb.11.6.7946395","article-title":"Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline","volume":"11","author":"Voelkel","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.autrev.2023.103506_bb0730","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.201809-1631LE","article-title":"IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB\/II pilot study","volume":"199","author":"Trankle","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103506_bb0735","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2019-0431OC","article-title":"Targeting Jak-Stat signaling in experimental pulmonary hypertension","volume":"64","author":"Yerabolu","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.autrev.2023.103506_bb0740","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar4051","article-title":"Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study","volume":"14","author":"Ngian","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103506_bb0745","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cjca.2014.04.016","article-title":"Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis","volume":"30","author":"Caldeira","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2023.103506_bb0750","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103506_bb0755","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0760","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103506_bb0765","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004757","article-title":"Is anticoagulation beneficial in pulmonary arterial hypertension?","volume":"11","author":"Khan","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.autrev.2023.103506_bb0770","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2020.08.024","article-title":"Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis","volume":"196","author":"Wang","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2023.103506_bb0775","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011028","article-title":"Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol","volume":"6","author":"Calderone","year":"2016","journal-title":"BMJ Open"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:24:18Z","timestamp":1715361858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223002409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":168,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1568997223002409"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103506","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103506"}}